Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies
- PMID:23806160
- DOI: 10.1016/j.clindermatol.2013.01.010
Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies
Abstract
Scleroderma refers to a heterogeneous group of autoimmune fibrosing disorders. The nomenclature of scleroderma has changed dramatically in recent years, with morphea (localized scleroderma), limited cutaneous systemic sclerosis, diffuse cutaneous systemic sclerosis, and systemic sclerosis sine scleroderma encompassing the currently accepted disease subtypes. Major advances have been made in the molecular studies of morphea and systemic sclerosis; however, their etiologies and pathogenesis remain incompletely understood. Although morphea and systemic sclerosis demonstrate activation of similar inflammatory and fibrotic pathways, important differences in signaling pathways and gene signatures indicate they are likely biologically distinct processes. Morphea can cause significant morbidity but does not affect mortality, whereas systemic sclerosis has the highest disease-specific mortality of all autoimmune connective tissue diseases. Treatment recommendations for morphea and systemic sclerosis are based on limited data and largely expert opinions. Current collaborative efforts in morphea and systemic sclerosis research will hopefully lead to better understanding of the etiology and pathogenesis of these rare and varied diseases and improved treatment options.
Published by Elsevier Inc.
Similar articles
- Retinoic acid for treatment of systemic sclerosis and morphea: A literature review.Thomas RM, Worswick S, Aleshin M.Thomas RM, et al.Dermatol Ther. 2017 Mar;30(2). doi: 10.1111/dth.12455. Epub 2016 Dec 29.Dermatol Ther. 2017.PMID:28032675Review.
- Localized scleroderma.Kreuter A.Kreuter A.Dermatol Ther. 2012 Mar-Apr;25(2):135-47. doi: 10.1111/j.1529-8019.2012.01479.x.Dermatol Ther. 2012.PMID:22741933Review.
- Morphea and Eosinophilic Fasciitis: An Update.Mertens JS, Seyger MMB, Thurlings RM, Radstake TRDJ, de Jong EMGJ.Mertens JS, et al.Am J Clin Dermatol. 2017 Aug;18(4):491-512. doi: 10.1007/s40257-017-0269-x.Am J Clin Dermatol. 2017.PMID:28303481Free PMC article.Review.
- Morphea and localized scleroderma in children.Vierra E, Cunningham BB.Vierra E, et al.Semin Cutan Med Surg. 1999 Sep;18(3):210-25. doi: 10.1016/s1085-5629(99)80019-4.Semin Cutan Med Surg. 1999.PMID:10468041Review.
- [Diagnostic and therapeutic problems of scleroderma].Pogorzelska-Antkowiak A, Antkowiak R.Pogorzelska-Antkowiak A, et al.Wiad Lek. 2006;59(5-6):392-5.Wiad Lek. 2006.PMID:17017489Review.Polish.
Cited by
- Controversy around the morphea.Dańczak-Pazdrowska A, Cieplewicz P, Żaba R, Adamski Z, Polańska A.Dańczak-Pazdrowska A, et al.Postepy Dermatol Alergol. 2021 Oct;38(5):716-720. doi: 10.5114/ada.2021.106242. Epub 2021 May 18.Postepy Dermatol Alergol. 2021.PMID:34849114Free PMC article.Review.
- Oral rehabilitation with dental implants in patients with systemic sclerosis: A systematic review.Mosaddad SA, Abdollahi Namanloo R, Ghodsi R, Salimi Y, Taghva M, Naeimi Darestani M.Mosaddad SA, et al.Immun Inflamm Dis. 2023 Mar;11(3):e812. doi: 10.1002/iid3.812.Immun Inflamm Dis. 2023.PMID:36988245Free PMC article.Review.
- Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway.Liu M, Yang J, Xing X, Cui X, Li M.Liu M, et al.Arthritis Res Ther. 2014 Dec 31;16(6):4223. doi: 10.1186/s13075-014-0512-2.Arthritis Res Ther. 2014.PMID:25551434Free PMC article.
- Fat Grafting Reduces Skin Hyperpigmentation of Localized Scleroderma Patients: A Prospective Self-controlled Study.Li Z, Wang HC, Chen J, Li Y, Yu N, Xiao Y, Du F, Wang X, Huang J, Long X.Li Z, et al.Aesthetic Plast Surg. 2023 Oct;47(5):2084-2092. doi: 10.1007/s00266-023-03543-4. Epub 2023 Aug 17.Aesthetic Plast Surg. 2023.PMID:37592146
- Skin, Autoimmunity and Inflammation: A Comprehensive Exploration through Scientific Research.Diotallevi F, Offidani A.Diotallevi F, et al.Int J Mol Sci. 2023 Nov 1;24(21):15857. doi: 10.3390/ijms242115857.Int J Mol Sci. 2023.PMID:37958840Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical